(Picture
from http://www.pbs.org/)
Following the widespread
use of poliovirus vaccine in the mid-1950s, the incidence of poliomyelitis
declined rapidly in many industrialized countries. In the United States,
the number of cases of paralytic poliomyelitis reported annually declined
from >20,000 cases in 1952 to <100 cases in the mid-1960s. The last
documented indigenous transmission of wild poliovirus in the United States
was in1979. In 1985, the member countries of the Pan American Health Organization
adopted the goal of eliminating poliomyelitis from the Western Hemisphere
by 1990. The strategy to achieve this goal included increasing vaccination
coverage; enhancing surveillance for suspected cases (i.e.,surveillance
for acute flaccid paralysis); and using supplemental immunization strategies
such as national immunization days (NIDs), house-to-house vaccination,
and containment activities. Since 1991, when the last wild-virus-associated
indigenous case was reported from Peru, no additional cases of poliomyelitis
have been confirmed despite intensive surveillance. In September 1994,
an international commission certified the Western hemisphere to be free
of indigenous wild poliovirus. The commission based its judgment on detailed
reports from national certification commissions that had been convened
in every country in the region. In 1988, the World Health Assembly (the
governing body of the World Health Organization) adopted the goal of global
eradication of poliomyelitis by the year 2000. Substantial progress toward
meeting this objective has already been achieved in many WHO regions, including
East Asia, the Middle East, Southern and Eastern Africa,and Europe. By
the end of 1998, almost all polio-endemic countries had conducted NIDs.
The number of reported cases of paralytic polio, as well as the number
of countries reporting cases, has decreased significantly since the global
eradication program began. In 1997, over half of all polio was reported
from the Indian subcontinent (the S.E. Asian region of WHO). Polio is still
endemic in parts of the Eastern Mediterranean and Africa. While
30 countries worldwide are still considered polio-endemic, intense activities
are currently targeted towards interrupting virus transmission in ten remaining
priority countries facing particular challenges:
Why
should eradication be successful?
a. There are no animal reservoirs
b. The virus is not airborne
c. There are only three serotypes
d. Poliovirus entry into cells is very inefficient
e. There are presently 2 effective vaccines
f. One of the vaccines (OPV) can be given orally and is inexpensive
g. Wild type viruses have been eliminated in much of the developed
world
Keys
to successful vaccination program in endemic countries:
a. Public health infrastructure
b. Community health education
c. Proper vaccine storage
d. Vaccine provided at a convenient time and place
e. Popular support, active participation of community leaders
and the community itself
How
should worldwide vaccination proceed?
Vaccinations done in endemic countries with OPV until wild poliovirus
circulation is minimal. Afterwards, IPV vaccinations should be used worldwide.
Exterminating OPV will minimize the risk of generating harmful poliovirus
by mutation and recombination. The use of IPV will lead to an increase
in the costs necessary to continue the eradication program. IPV vaccination
can be stopped when it is certain that wild poliovirus, OPV, and mutant
or recombinant strains are no longer circulating. In addition, measures
must have been taken to exclude virus escape from laboratories and vaccine
factories. A combination of efforts should be applied, including AFP surveillance,
serological tests, and tests of sewage and feces samples to acertain the
level of circulating poliovirus.
Research
Topics Important to the Eradication Initiative:
·Characterizing
RNA sequences that determine transmissibility and determining the possibility
that such sequences develop by genetic drift or recombination.
·Developing
serological tests that are able to detect infected persons in IPV-vaccinated
populations.
The facts that both OPV and IPV induce
high levels of immunity and that OPV is relatively inexpensive to develop
and distribute,have hampered efforts
to create novel vaccines. OPV is highly effective at eliminating wild type
poliovirus, and IPV is effective at eliminating vaccine virus reversions
that can lead to VAPP.
AFR = African
Region, AMR = American Region, EMR = Eastern Mediterranean Region, EUR
= European Region, SEA = South-East Asian Region,
WPR = Western
Pacific Region. Click here
for specfic countries in each region as defined by the World Health Organization.
(Statistics taken from WHO:http://www.who.int/
)

(Picture taken from http://www.cdc.gov/epo/mmwr/preview/mmwrhtml/00053047.htm)
Additional
Links Relevant to Eradication Programs:
1.For
Current List of Year 2000 Global National Immunication Days.